🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are increasing around the world, with data suggesting over 82 million infections annually. Notably increased rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, was also approved in close succession. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

According to findings detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which combines a dual-drug approach. The research involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the authority to register and commercialise the drug in many regions with limited resources.

Medical professionals directly involved have expressed optimism. Having a single-dose, oral treatment like this is hailed as a "game-changer" for managing the epidemic. This is considered vital to lessen the impact of the infection for individuals and to stop the proliferation of untreatable gonorrhoea globally.